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Aim. The purpose of this study was to determine the in vitro response of cells critical to the wound healing process in culture media
supplemented with a lyophilized preparation rich in growth factors (PRGF) and Manuka honey. Materials and Methods. This study
utilized cell culture media supplemented with PRGF, as well as whole Manuka honey and the medical-grade Medihoney (MH), a
Manuka honey product. The response of human fibroblasts (hDF), macrophages, and endothelial cells (hPMEC) was evaluated,
with respect to cell proliferation, chemotaxis, collagen matrix production, and angiogenic potential, when subjected to culture
with media containing PRGF, MH, Manuka honey, and a combination of PRGF and MH. Results. All three cell types demonstrated
increases in cellular activity in the presence of PRGF, with further increases in activity seen in the presence of PRGF+MH. hDFs
proved to be the most positively responsive cells, as they experienced enhanced proliferation, collagen matrix production, and
migration into an in vitro wound healing model with the PRGF+MH-supplemented media. Conclusion. This preliminary in vitro
study is the first to evaluate the combination of PRGF and Manuka honey, two products with the potential to increase regeneration
individually, as a combined product to enhance dermal regeneration.

1. Introduction
The dermal healing response is a multistep process (inflammation, granulation tissue proliferation, epithelialization,
and remodeling of the wound site) which may result in
a number of diﬀerent outcomes: complete healing, scarred
healing, or a chronic nonhealing wound [1, 2].
In nonhealing wounds, such as pressure and diabetic
ulcers, the carefully coordinated wound healing process has
been altered. Neutrophils accumulate in the wound site
and leave the wound stuck in a state of chronic inflammation. While inflammation normally resolves within 1-2
days as neutrophil number decreases, the prolonged presence of these cells contributes to a disordered network of

regulatory cytokines. This aberrant set of regulatory signals has far-reaching eﬀects on all the cells involved in
dermal healing (macrophages, fibroblasts, etc.) and results
in increased proteolytic activity and improper extracellular
matrix (ECM) deposition. In order for these wounds to heal,
the self-propagating loop of chronic inflammation must be
disrupted. Current clinical treatments often center around
surgical debridement, exudate management, and minimization of bacterial adherence (biofilm) to remove inflammatory stimuli. Other treatments involve the utilization of
recombinant growth factors, synthetic protease inhibitors, or
pH modifying ointments [1, 2]. However, to date, there has
been no single treatment that has proven to be optimal at
stimulating the resolution of chronic wounds, and the future
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may lie in regenerative medicine’s ability to modify cellular
behavior within the wound site.
Honey had been used medicinally for centuries, due to its
inherent wound healing capacity. However, the introduction
of penicillin significantly reduced its role [3–8]. Recently,
with the emergence of antibiotic-resistant bacteria and a
better scientific understanding of how honey influences
healing, honey (specifically active Leptospermum honey from
New Zealand, known as Manuka) has once again become an
acceptable product in the treatment of wounds. The major
benefit of Manuka honey lies in its potent antibacterial
properties. Honey has a high osmolarity and a high sugar
content, the combination of which has been shown to inhibit
microbial growth [5, 9, 10]. Manuka honey is also known
to have a relatively low pH (3.5–4.5), which, in addition to
inhibiting microbial growth, will stimulate the bactericidal
actions of macrophages, and in chronic wounds reduce
protease activity, increase fibroblast activity, and increase
oxygenation [5, 10–12]. Hydrogen peroxide is slowly released
from honey placed on a wound through the interaction of
wound exudates with the honey’s inherent glucose oxidase.
This hydrogen peroxide is in suﬃcient concentration to be
antibacterial, yet dilute enough to be nontoxic while promoting fibroblast proliferation and angiogenesis [3, 5, 9, 10, 12].
Manuka honey also possesses nonperoxide antibacterial
activity in what is called the Unique Manuka Factor (UMF)
due to the presence of methylglyoxal [6, 12].
Honey has been shown to contain a number of phenolic
compounds, which are known to scavenge and remove reactive oxygen species (ROS) released by neutrophils [6]. Leong
et al. [6] demonstrated that honey can suppress oedema
and leukocyte infiltration in a mouse model of neutrophilic
inflammation. Tonks et al. [7] demonstrated that monocytes
cultured in the presence of honey were stimulated to produce
a number of pro and anti-inflammatory cytokines (tumor
necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β),
and interleukin-6 (IL-6)) and may indicate modulation
towards resolution in nonhealing wounds.
Platelet-rich plasma (PRP) therapy has been gaining
momentum as a bedside regenerative medicine procedure
and has been used to stimulate regeneration of osteochondral defects [13–15], tendon/ligament injuries [13–19], and
chronic dermal wounds (diabetic and pressure ulcers) [14,
15, 20, 21] in clinical studies. PRP is a simple and costeﬀective method for collecting and concentrating autologous
platelets (some clinical studies have published on the use of
pooled-banked PRP in order to overcome donor variability
with no evidence of immunoreactions [22–25]) for the
purpose of activating and releasing their growth factor-rich
alpha and dense granules. These granules releases a number
of growth factors and cytokines, including: platelet-derived
growth factor (PDGF), transforming growth factor beta
(TGF-β), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), epidermal growth factor (EGF),
and others [13, 15, 16, 20, 26–28]. These listed factors, in
conjunction with the numerous factors contained in PRP
not listed, are known to accelerate cell migration and proliferation, promote ECM production, as well as play a role in
macrophage phenotype and inflammation resolution [13, 26,
27, 29–33].
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There is currently no consensus as to how PRP should be
most eﬀectively utilized in the treatment of wounds. There
have been a number of methods reported on delivering PRP;
most involve the creation of an activated-platelet gel with
thrombin [13–15, 34] or CaCl2 [13–15, 28]. These PRP gels
are easily applied to wound sites through injection or topical
application. However, studies have shown that the use of
these PRP gels are ineﬃcient due to the rapid release and
diﬀusion of the factors [13]. Several techniques have been
evaluated for sustained release, including gelatin gel microspheres [35], lyophilized PRP [36–39], and alginate beads
[40]. Collectively, these studies demonstrated the importance
of keeping preparations rich in growth factors (PRGF)
in the wound site and slowly activating/releasing them as the
wound site becomes infiltrated with reparative cells.
The purpose of this study was to determine the in vitro
response of three cell types critical to wound healing (fibroblasts, endothelial cells, and macrophages) when subjected to
culture media supplemented with Manuka honey, a powdered PRGF (a lyophilized version of PRP), or a combination
of Manuka honey and PRGF. The hypothesis being that
Manuka honey and PRGF will increase cellular activity over
control media, with a corollary that the combination of
honey and PRGF will provide the greatest increase due to
increased growth factor and cytokine activity through acid
activation. Manuka honey has been documented to have an
acidic pH, and factors such as TGF-β are known to become
physiologically active when subjected to an acid treatment.

2. Materials and Methods
2.1. Creation of PRP/PRGF and Honey Media. PRP and
PRGF were created using previously described methods [41,
42]. Briefly, fresh human whole blood from 3 donors was
purchased (Biological Specialty Corp., Colmar, PA, USA),
pooled, and used in a SmartPReP 2 (Harvest Technologies
Corp., Plymouth, MA, USA) centrifugation system to create
PRP per manufacturers protocol. PRP was then subjected
to a freeze-thaw-freeze (FTF) cycle in a −70◦ C freezer for
cell lysis (centrifuge tubes containing PRP were placed in
a −70◦ C freezer for 24 hrs followed by a 37◦ C water bath
for 1 hr, and then returned to the −70◦ C freezer for 24 hrs).
Frozen PRP was then lyophilized for 24 hrs to create a dry
PRGF powder which was finely ground in a mortar and pestle
prior to use. This dry PRGF powder was added to the test
media used in this study as a weight percentage (w/w %).
The honeys used in this study were a pure Manuka honey
(Wedderspoon Organic, UMF 16+, Vancouver Island, BC,
Canada) and Medihoney (MH, DermaSciences Inc., Princeton, NJ, USA), which is a medical grade, sterile, Manuka
honey that has been filtered to remove any potential residual
pollen or bee byproducts. Honeys were added to test medias
as a volume percentage (v/v %).
2.2. Western Blot Analysis of Honey-Activated PRP. It has
been previously documented that TGF-β can be transformed from a nonactive state to a physiologically active
form through pH modification (TGF-β ELISA instructions).
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To determine what, if any, activation potential the honey
(pH known to be 3.5–4.5) aﬀorded, PRP was mixed in
varying ratios (1 : 1, 1 : 5, 1 : 10, 5 : 1, and 10 : 1) with MH
and subjected to a modified Western Blot to determine
physiologically active TGF-β through fluorescence. Briefly,
the PRP : MH solutions were blotted on a PVDF membrane,
along with PRP that was acid activated using a modified
TGF-β ELISA protocol (Promega, Madison, WI, USA). The
membrane was blocked in Odyssey Blocking Buﬀer for
one hour at room temperature. After blocking, samples
were incubated in anti-human TGF-β antibody (Promega,
Madison, WI, USA) at room temperature for 1.5 hours. All
samples were then washed four times with 0.1% Tween-20 in
PBS, after which the signal from anti-human TGF-β antibody
was detected with goat anti-mouse IgG secondary antibody
tagged with a fluorescent 800 nm marker (Thermo Scientific,
Waltham, MA, USA). To account for antibody background
fluorescence, each sample was also incubated with secondary
antibody only. Samples were incubated in the secondary
antibody for 1 hour at room temperature without exposure
to light. After washing, the samples were scanned using the
800 nm channel of the Odyssey Infrared Imaging System
(LI-COR Biosciences, Lincoln, NE, USA) at an intensity of
3.5. Fluorescence intensities were measured using circular
gates that completely surrounded each sample. Background
fluorescence that was obtained from samples incubated with
secondary antibody only was subtracted from the signal
intensities of the samples incubated with both primary and
secondary antibodies.
2.3. Eﬀect of PRGF and Honey on Cell Proliferation. Human
dermal fibroblasts (hDF) were seeded subconfluently in
a 48-well plate at 50,000 cells/well in 500 μL of control
media (DMEM/F12 supplemented with 10% fetal bovine
serum (FBS), 1% penicillin/streptomycin (P/S)). Following
adhesion of cells to the well-plate (∼2 hrs) control media
was replaced with test media (control media supplemented
with Manuka honey in 0.1, 1, 5, 10, or 20% v/v, MH in 0.1,
1, 5, 10, or 20% v/v, PRGF in 0.1, 1, 5, or 10 mg/mL or a
combination of 0.1% MH and 1 mg/mL PRGF). Test media
was changed on days 1, and 4, with an MTS assay (CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay,
Promega, Madison, WI, USA) performed on days 1, 4, and 7
to determine mean cell count.
Using a protocol nearly identical to that of the hDF proliferation study, immortalized human pulmonary microvascular endothelial cells (hPMEC, donated generously from
Dr. C. J. Kirkpatrick) were seeded subconfluently at 25,000
cells/well in a 48-well plate in 500 μL of control media (M199
media supplemented with 10% FBS, 1% P/S, Glutamax 100x,
G418, heparin sodium salt (50 μg/mL), and endothelial cell
growth supplement (ECGS, 50 μg/mL)). Following adhesion
of cells to the well-plate (∼2 hrs) control media was replaced
with test media (control media supplemented with Manuka
honey in 0.1, 1, 5, 10, or 20% v/v, MH in 0.1, 1, 5, 10, or 20%
v/v, PRGF in 0.1, 1, 5, or 10 mg/mL or a combination of 0.1%
MH and 1 mg/mL PRGF). Test media was changed on days 1,
and 4, with an MTS assay performed on days 1, 4, and 7 to
determine mean cell count.
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Human peripheral blood macrophages (ATCC,
CRL9855) were seeded subconfluently in a 48-well plate at
50,000 cells/well in 500 μL of control media (RPMI 1640,
supplemented with 10% FBS, 1% P/S). Following adhesion
of cells to the well-plate (∼2 hrs) control media was replaced
with test media (control media supplemented with either
Manuka honey or MH in 0.1, 1, 5, 10, or 20% v/v). Test media
were changed on days 1, 4, and 7, and an MTS assay was
performed on the same time points to determine a mean cell
count. Changed media was retained and used for subsequent
ELISA analysis to determine what role the honey may play in
stimulating macrophage inflammation. PRGF supplemented
media was not investigated with this cell type as previous
work has demonstrated that the presence of PRGF had little
impact on macrophage proliferation [42].
2.4. Macrophage Inflammation Response. Using the retained
media from the proliferation study, ELISAs were run per
manufacturer’s protocol to determine the inflammatory
response of macrophages to either pure Manuka honey or
MH. ELISAs were conducted to determine levels of TNF-α
(Antigenix America Inc., Huntington Station, NY, USA), an
indicator of inflammation and M1 phenotype, Interleukin10 (IL-10, Peprotech, Rocky Hill, NJ, USA), an interleukin
commonly associated with inflammation resolution and a
regulatory phenotype, and VEGF (Antigenix America Inc.),
which is critical to angiogenesis and is expressed by M2
macrophages.
2.5. Eﬀect of PRGF and Honey on Cell Chemotaxis. Similar to
the aforementioned cell proliferation studies, cell chemotaxis
studies were conducted on both macrophages and hPMECs
(hDF chemotaxis was evaluated with an in vitro wound healing assay) using a transwell plate and an MTS assay. Human
macrophages were seeded in the top insert of a transwell plate
(8 μm diameter pores, Corning Inc., Lowell, MA, USA) with
50,000 cells/well in 200 μL control media, while the bottom
insert was filled with 600 μL of test media (control media
supplemented with Manuka honey in 0.1, 1, 5, 10, or 20%
v/v, MH in 0.1, 1, 5, 10, or 20% v/v, PRGF in 0.1, 1, 5,
or 10 mg/mL or a combination of 0.1% MH and 1 mg/mL
PRGF). Media from both the top insert and the bottom well
were changed on days 1, and 2, and the cells were counted
using an MTS assay on day 3. The MTS assay was performed
on both inserts and the bottom wells to distinguish between
cell chemotaxis and proliferation. This study was then
repeated with hPMECs.
2.6. In Vitro Wound Healing Assay. An in vitro wound healing
assay was performed to determine the rates of migration
of hDFs into a wound site, simulating hDF migration into
dermal wounds in vivo [43]. A 48-well plate was coated with
fibronectin (10 μg/mL) and blocked with bovine serum albumin (2 mg/mL) prior to cell seeding. The exterior underside
of each well was marked with a permanent marker to serve
as a reference line. Each well was then seeded to confluency
with 100,000 hDFs in a standard DMEM/F12 control media
(containing 1% P/S, and 2% FBS to minimize cellular
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proliferation). The cells were allowed to attach and spread
overnight, creating a completely uninterrupted layer of cells.
After 18 hrs, a 200 μL pipette tip was scraped across the well,
perpendicular to the reference line to create an intersection
point, to create the in vitro wound. The wells were gently
washed with control media to remove any dislodged cells,
and test media was added. Test media consisted of control
media supplemented with 1% v/v MH, 1 mg/mL PRP, and
a combination of 1% v/v MH and 1 mg/mL PRP (chosen
based upon results of hDF proliferation study). Images were
taken at time 0, 6, 12, 18, and 30 hr using an inverted Nikon
microscope with a 4x objective and color camera. Using the
reference intersection point, images were taken at the same
location at each successive time point. Using image analysis
software (ImageTool), the area of each wound was measured,
and a rate of healing was determined.
2.7. Hydroxyproline Assay. To determine the amount of
ECM produced by the hDFs, a hydroxyproline assay was
performed based upon previously published protocols [44–
46]. Briefly, hDFs were seeded near confluency at 100,000
cells/well in a 48-well plate in 500 μL of control media.
Following adhesion of cells to the well-plate (∼2 hrs) control
media were replaced with test media (control media supplemented with 1% MH v/v, 1 mg/mL PRGF, or a combination
of 1% MH and 1 mg/mL PRGF). These specific test media
were chosen for evaluation based upon results of previous
hDF experiments conducted in this study. Media was
changed every other day and retained for assessment with
the assay on days 1, 7, 14, 21, and 28. Retained media was
hydrolyzed in 100 μL of 6 M hydrochloric acid in a boiling
water bath and subsequently lyophilized until dry. Dry
samples were diluted in 50 μL of distilled water, and 450 μL
of chloramine T reagent were added and allowed to oxidize
in the dark at room temperature for 25 minutes. 500 μL
Ehrlich’s reagent added to each sample, mixed gently, and
incubated for 20 minutes at 60◦ C. 100 μL of each sample were
then transferred to a 96-well plate and read at 570 nm on
a spectrophotometer (SpectraMax Plus, Molecular Devices,
Sunnyvale, CA, USA).
2.8. In Vitro Bead Angiogenesis Assay. A preliminary in vitro
angiogenesis bead assay was performed, similar to that of
Chen, et al. [47]. After Cytodex microcarrier beads (SigmaAldrich, St. Louis, MO, USA) were autoclaved and hydrated
overnight, 10 μL of bead solution was placed in a 15 mL
tube and rinsed 3 times with complete hPMEC medium
before being mixed with approximately 1 million hPMEC.
The tube was incubated in standard conditions (37◦ C, 5%
CO2 ), with inversion of the tube occurring every half hour
over 3 hours to ensure cells attached to the beads. The media
was then removed from the centrifuge tube, placed in a flask,
and incubated overnight. After incubation, beads were rinsed
in PBS and transferred back to a 15 mL tube. Once the
beads had settled to the bottom, any remaining media were
removed, and beads were washed once more with PBS. After
allowing the beads to settle to the bottom of the tube a
second time, the beads with adherent cells were resuspended
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in a collagen gel solution (80% liquid Purecol with 10%
0.1 M NaOH and 10% 10X PBS) containing 1000 KIU/mL
aprotinin (Sigma-Aldrich, St. Louis, MO, USA). Simultaneously, 250 μL of collagen gel solution with aprotinin was
placed in the bottom of a 24 well plate and incubated at
standard conditions until gelation occurred. Once the first
layer was gelled, 250 μL of cell suspension was placed on the
first collagen gel layer and was incubated for 2 hours to again
allow for gelation. Supplemented media was then created
as described previously (Manuka honey in 0.1, 1, 5, 10, or
20% v/v, MH in 0.1, 1, 5, 10, or 20% v/v, PRGF in 0.1, 1,
5, or 10 mg/mL or a combination of 0.1% MH and 1 mg/mL
PRGF) and 500 μL was placed on top of the gel solution
containing the cell covered beads and incubated under
standard conditions for 6 days. At days 1, 4, and 6, images
were captured using a Nikon Eclipse TE200 microscope with
a Dage-MTS digital camera. Three images were taken for
each test media at each time point. To quantify the percentage
of hPMEC sprouts per bead, a circular grid was overlayed
onto each bead, dividing it into 36 sections. All sprouts
extending from the surface of the beads were counted,
summed, and divided by 36 to determine the percentage of
sprouts for each bead. In addition, the length of each sprout
extending from the surface of the beads was quantified using
ImageTool 3.0 software (Shareware provided by UTHSCSA).
Results are presented as average sprout length per bead
(n = 3).
2.9. Statistical Analysis. All statistical analysis was based on
a Kruskal-Wallis one-way ANOVA on ranks and a TukeyKramer pairwise multiple comparison procedure (α = 0.05)
performed with the JMP IN 8.0 statistical software package
(SAS Institute, Inc.). Graphical depictions of mean data
were constructed with Microsoft Excel 2007, with error bars
representing standard deviations from the mean. All studies
were done in triplicate (n = 3).

3. Results
3.1. Western Blot Analysis of Honey-Activated PRP. The
Western blot analysis of honey-induced PRP activation is
shown in Figure 1. While the modified Western blot analysis
used in this study does not provide an exact quantification
of physiologically active TGF-β, the diﬀerences in sample
fluorescence can be used to provide a general indication
about the presence of TGF-β activated through either acid
or honey treatment. Statistical analysis revealed there to be
no significant diﬀerences in activated TGF-β regardless of
whether PRP was activated through acid treatment or mixing
with MH. Additionally, both the acid and MH-treated PRP
was significantly more fluorescent than the unactivated PRP.
3.2. Eﬀect of PRGF and Honey on Cell Proliferation. Results
of the hDF, hPMEC, and macrophage proliferation studies
are shown in Figure 2. hDF proliferation was observed over
7 days in response to test medias containing varying concentrations of Manuka honey, MH, PRGF, and a combination
of PRGF+MH, and cell numbers ranged from near 0 for
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control all being statistically the same. As before, there were
no significant diﬀerences between the Manuka honey and
MH supplemented medias.
The macrophage proliferation study was conducted without the addition of PRGF, as a previous study revealed that
macrophage proliferation was not significantly influenced by
the presence of PRGF [42]. Therefore, macrophage proliferation was compared between test medias containing pure
Manuka honey and MH. Macrophage cell numbers ranged
from near 0 for higher honey concentrations to over 286,000
for the 0.1% Manuka honey at day 4. Statistical analysis
revealed there to be no significant diﬀerences between test
medias of Manuka honey and MH at the same concentration.
Macrophage proliferation peaked at day 4 for the 0.1 and 1%
Manuka and MH test medias, at which point cells became
contact inhibited and cell number decreased for day 7.

Honey activated

(a)
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30
Fluorescence

25
20
15
10
5
0
PRP

1:1

1:5
1 : 10
Ratio (PRP : MH)

5:1

10 : 1

Acid activated
Honey activated
Unactivated
(b)

Figure 1: (a) Fluorescence results from TGF-β western blot for
acid- and honey-activated PRP. All ratios are PRP : MH by volume.
(b) Quantification of fluorescence from TGF-β Western blot.

the higher Manuka/MH concentrations to greater than
224,000 for the PRGF+MH on day 7. Statistical analysis
revealed the combination of PRGF+MH to significantly
enhance cell proliferation over all other groups at days 4 and
7. Additionally, the presence of PRGF alone had a greater
impact on cell proliferation than MH alone, as 0.1, 1, and
5 mg/mL PRGF had significantly higher cell numbers than
the 0.1 or 1% MH. There were no significant diﬀerences
between Manuka honey and MH-supplemented media of the
same concentration at any time point.
The results of the hPMEC proliferation study were
similar to those of the hDF study, with cell numbers ranging
from near 0 for the higher Manuka/MH concentrations to
over 101,000 for the PRGF+MH test media. However, the
diﬀerences between the PRGF+MH and the other test media
were not as pronounced as with the hDF study. While the
PRGF+MH had the highest average cell number at day 7, it
was not statistically diﬀerent from the 1 mg/mL PRGF test
media at day 7 (P = 0.1343). Additionally, there were few
diﬀerences seen between test medias on day 4 as well; with
the PRGF+MH, 1 and 5 mg/mL PRGF, 0.1 and 1% MH, and

3.3. Macrophage Inflammation Response. Results of the
macrophage inflammation response ELISAs are shown in
Figure 3. Media used in the macrophage proliferation study
was retained and analyzed through ELISA for the presence of
TNF-α, IL-10, and VEGF; three cytokines that can provide
insight into macrophage function and phenotype. For the
TNF-α ELISA, the 1% Manuka test media yielded the
only significant result, with a peak TNF-α concentration of
0.48 ng/mL on day 1 and significant decreases in TNF-α at
days 4 and 7. The IL-10 ELISA results ranged from 0 for 5%
Manuka on day 7 to 0.13 ng/mL for the control at day 7.
Statistically, the control media on days 4 and 7 were significantly diﬀerent from all other groups, with the exception of
the 0.1% Manuka on day 7, 0.1% MH on day 7, and the 20%
Manuka on day 1. The 20% Manuka day 1 results are most
likely outliers as the 20% Manuka proved to be cytotoxic.
While there appears to be a trend of increasing IL-10 release
from the lower honey concentrations (0.1 and 1%), these
increases were not statistically significant. Values of VEGF
release ranged from 0.06 to 0.19 ng/mL for 5% Manuka on
day 1, and 0.1% Manuka on day 4, respectively. Test media
were not statistically diﬀerent from one another, with the
exception of the 0.1% Manuka on day 4 and the 10% MH on
day 1, and these were most likely outliers as there is no logical
explanation for such a random spike in VEGF production.
While there does appear to be a trend of increasing VEGF
over time for all samples, the diﬀerences were not significant.
3.4. Eﬀect of PRGF and Honey on Cell Chemotaxis. The
results of the macrophage and hPMEC chemotaxis are shown
in Figure 4. The presence of Manuka/MH did not induce
significant macrophage chemotaxis, but did increase cell
proliferation in the insert at the lower MH concentrations.
Similar to the results of the cell proliferation studies, there
were no significant diﬀerences between the pure Manuka
honey and the MH medias. The higher honey concentrations
(5, 10, and 20% v/v) resulted in cell death and are therefore
not included in Figure 4. The 10 mg/mL PRGF resulted in a
statistically significant increase in chemotaxis to the bottom
well over the control media, but did not induce a statistically significant increase in cell proliferation in the insert.
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Figure 2: Results of mean hDF (a), hPMEC (b), and macrophage (c) proliferation from MTS assays at days 1, 4, and 7. Manuka honey
results are not shown for hDF and hPMEC proliferation as they were not statistically diﬀerent from MH.

The combination of PRGF+MH contributed mainly to the
proliferation of macrophages, with the PRGF+MH insert
experiencing the largest increase in cell number (significant
over all other groups) with chemotaxis that was not significantly diﬀerent from those of the control media. The 10 mg/
mL PRGF formed a clot when added to the media, making it
diﬃcult to ensure accurate cell counting with the MTS. While
reasonable numbers were achieved, their accuracy cannot be
assured due to the clot formation and potential loss of cells.
hPMEC chemotaxis was also minimal, with only the
5 and 10 mg/mL PRGF inducing a statistically significant
amount of cells to travel from the insert to the bottom well.
These test media actually formed a semisolid clot, making it
diﬃcult to accurately assess cell number in the bottom well
as cells seemed to readily migrate into the clot. The 1% MH,
PRGF+MH, and 0.1 mg/mL PRGF all stimulated significant
cellular proliferation over control media in the insert, but did
not induce chemotaxis.
Future studies will utilize a longer time course for chemotaxis studies, as the 72 hrs in this study may not have been

long enough to see cellular chemotaxis on a quantifiable
scale.
3.5. In Vitro Wound Healing Assay. Results of the in vitro
wound healing assay are shown in Figure 5. The combination
of PRGF+MH demonstrated more rapid hDF infiltration
into the denuded area compared to all other groups at
time points 12 and 18 hrs. By the 30 hr time point, the
wounded area in the PRGF+MH group was indistinguishable
from surrounding areas, whereas the other groups still
contained small areas of exposed culture plastic. However,
while there was a trend towards increased healing with the
PRGF+MH over all other medias, these diﬀerences were not
all statistically significant due to a limited sample population.
The PRGF+MH exhibited significantly more healing than the
controls at 30 hr, but was not significantly diﬀerent from the
PRGF or the MH medias at the same time point. At the 18 hr
time point both the PRGF+MH and PRGF were significantly
diﬀerent from control media, while not statistically diﬀerent
from one another. The largest jump in area healed occurred

7

(a)

Control

20% MH

20% Manuka

0.1% Manuka

Control

20% MH

20% Manuka

10% MH

10% Manuka

5% MH

5% Manuka

1% MH

1% Manuka

0.1% MH

0.1% Manuka

0

10% MH

0.1

10% Manuka

0.2

5% MH

0.3

5% Manuka

0.4

1% MH

0.5

1% Manuka

0.6

0.18
0.16
0.14
0.12
0.1
0.08
0.06
0.04
0.02
0
0.1% MH

0.7
IL-10 concentration (ng/mL)

TNF-α concentration (ng/mL)

International Journal of Biomaterials

(b)

VEGF concentration (ng/mL)

0.3
0.25
0.2
0.15
0.1
0.05
Control

20% MH

20% Manuka

10% MH

10% Manuka

5% MH

5% Manuka

1% MH

1% Manuka

0.1% MH

0.1% Manuka

0

Day 1
Day 4
Day 7
(c)

Figure 3: Results of the macrophage inflammation response studies, with mean TNF-α (a), IL-10 (b), and VEGF (c) from days 1, 4, and 7.
Dashed lines indicate the minimum levels of detection of 0.031, 0.005, and 0.023 ng/mL for the TNF-α IL-10, and VEGF ELISAs, respectively.

with the PRGF+MH at the 12 hr time point (69% area
healed compared to 33% for control), which was significantly
diﬀerent from all other medias at that time.
3.6. Hydroxyproline Assay. The results of the hydroxyproline
assay are shown in Figure 6. Mean hydroxyproline con–
centrations ranged from 3.5 μg/mL for the PRGF+MH with
no cells to 7.9 μg/mL for the PRGF+MH on day 7. Results
indicate that hydroxyproline, and therefore collagen, content
peaked on day 7 for the PRGF and PRGF+MH and then
decreased to an almost steady concentration, potentially
due to cell proliferation resulting in contact inhibition and
apoptosis or loss of aggregated collagen through subsequent
media changes. Statistical analysis revealed the PRGF and
PRGF+MH to be statistically the same at the day 7 time
point, while superior to the MH and control medias at
the same time point. There were no significant diﬀerences
between test medias at the other time points.

3.7. In Vitro Bead Angiogenesis Assay. Results of the in vitro
bead angiogenesis assay are shown in Figure 7. Mean sprout
densities ranged from 2.7% for controls on day 1 to 90.7%
for the 1 mg/mL PRGF on day 6. Statistical analysis revealed
the 0.1 mg/mL PRGF, 1 mg/mL PRGF, and PRGF+MH to be
significantly diﬀerent from the control at day 6, with the
1 mg/mL PRGF and PRGF+MH not being diﬀerent from
each other. At day 4, only the 1 mg/mL PRGF was significantly diﬀerent from the control, while none of the test
medias were significantly diﬀerent from the control at day 1.
Mean sprout lengths ranged from 12.6 μm for control on day
1 to 100.5 μm for 1 mg/mL PRGF on day 6. Statistical analysis
of the mean sprout length data was fairly inconclusive due
to the large deviations in both sprout number and length
from bead to bead, however; it was determined that the
1 mg/mL PRGF was significantly diﬀerent from the control
on day 6. Trends in sprout length mean tend to indicate that
both sprout length and density increase with PRGF concentration. Throughout this study, the 5 and 10 mg/mL PRGF
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Figure 4: Results of macrophage (a) and hPMEC (b) chemotaxis from MTS assay quantification in both the top insert and bottom well. The
results of cell chemotaxis from the addition of Manuka honey are not included as they were not significantly diﬀerent from those of MH.
Higher honey concentrations (5, 10, and 20% v/v) were excluded as they resulted in cell death.

test medias suﬀered from gel formation which made their
analysis extremely diﬃcult and reported results unreliable.
Surprisingly, the Manuka and MH supplemented medias
proved to be rather unsuccessful at promoting sprout
formation, as the higher concentrations (5, 10, and 20% v/v)
resulted in hPMEC death and the lower concentrations failed
to demonstrate increases in sprout density or length over
control media.

4. Discussion
PRP, and the powdered PRGF used in this study, is an attempt
to harness the healing potential of the platelets and their
inherent growth factors to initiate and accelerate the body’s
normal healing response. While PRP and PRGF have been
investigated previously, this study was the first attempt at
enhancing their bioactivity through the addition of Manuka
honey, which in and of itself has been shown to be eﬀective
in treating chronic dermal wounds in a number of clinical
settings. This preliminary in vitro work investigated the
potential for PRGF and Manuka honey/MH to stimulate the
activity of hDF, hPMECs, and macrophages in ways that
would provide insight into their specific roles in the healing
process. Cell proliferation, chemotaxis, cytokine release, and
ECM production were all tested in the presence of PRGF and
Manuka honey media supplements in order to determine
what response, if any, each cell type had to the additives and
which additive/concentration proved to be most eﬃcacious.
PRP, in its liquid form has been used previously as a
media supplement in the culture of a number of cell lines
(hDFs, bone marrow and adipose derived mesenchymal stem
cells, patellar tendon fibroblasts, anterior cruciate ligament
fibroblasts) [34, 48–56]. These studies have all documented
that the addition of PRP to culture media resulted in

increased rates of cell proliferation or was at minimum
eﬀective in maintaining rates of cell proliferation in the
place of a traditional serum supplement. In this study, rather
than utilize PRP, a dry PRGF powder was created by subjecting PRP to a freeze-thaw-freeze process and subsequent
lyophilization. The creation of this powder allows for easier
handling of the material, while further concentrating its
contents through the removal of the liquid plasma portion.
Despite this processing, it has been previously demonstrated
that PRGF retains its bioactivity and can successfully impact
cellular activity [41, 42]. The use of the PRGF in this study
clearly demonstrates eﬀectiveness in stimulating cell proliferation, chemotaxis, matrix production, and angiogenesis.
The presence of PRGF-supplemented media promoted significant increases in the proliferation of hDFs and hPMECs
at lower concentrations, while higher concentrations resulted
in the formation of a clot that impeded accurate cell quantification. While this clotting action was definitely a hindrance
to obtaining accurate cell proliferation/chemotaxis results
in this study, it also demonstrated the retained inherent
activity of the PRGF powder. While determining the clotting
potential of the PRGF was not the intent of this study, this
result was seen as an added benefit and may prove beneficial
as a hemostatic product. Overall, the results of the use of
PRGF are similar to what has been previously published with
PRP. Namely, PRP can significantly increase the activity of
a number of diﬀerent cell types. The statistically significant
increases in hDF proliferation and migration, as well as the
increases in hPMEC proliferation and chemotaxis clearly
demonstrate that the cytokines present in the PRGF retain
their functionality after processing.
As noted, Manuka honey has been re-gaining popularity among the wound healing community [3, 5, 9–11,
57]. The rather unique properties possessed by the active
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Figure 5: Light microscopy images of the in vitro wound healing assay taken at time 0, 18, and 30 hr after wounding (a). Graph of the mean
% area healed for each of the test media at 6, 12, 18, and 30 hr after wounding (b).

Leptospermum honeys are all highly beneficial in tissue
regeneration. To evaluate the hypothesis that the low pH of
the Manuka honey would eﬀectively activate PRGF-derived
growth factors, the impact of Manuka honey supplemented
media on three distinct cell lines was evaluated. The modified
Western Blot performed demonstrated the presence of
activated TGF-β derived from the combination of MH and
PRP. While this test did not provide a quantitative assessment

of how much active TGF-β was present, it oﬀered a side by
side comparison of the two treatment methods and showed
them to be nearly identical. The presence of this activated
TGF-β, and potentially other acid activated cytokines, may
have played a major role in the impact that PRGF+MH had
in accelerating cellular activity.
Interestingly, throughout the study, there were no significant diﬀerences between the two honey products tested:
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Figure 6: Results of the hydroxyproline assay performed on
retained media on days 1, 7, 14, 21, and 28.

the pure Manuka honey and the medical grade MH. This
would indicate that the filtration and sterilization process
used to make the MH has no ill eﬀects on its eﬃcacy. The
only significant diﬀerence experienced between the two
products was seen in the macrophage inflammation response, where TNF-α release was significantly increased in
the 1% Manuka honey on days 1 and 4. This makes sense as
the release of TNF-α commonly indicates an inflammatory
response and an M1 macrophage phenotype [29–32, 58, 59].
It is completely possible, and highly likely, that the pure
Manuka honey may contain some amount of allergens or bee
byproducts that could induce an inflammatory response. It
would then make sense that the sterilized MH product would
be allergen and bee byproduct free. As small amounts of
IL-10 were produced by the macrophages during this study,
that may indicate that the macrophages expressed an antiinflammatory phenotype (regulatory macrophage). Looking
at macrophage phenotype as a highly plastic, continuous
spectrum, the regulatory macrophage serves as a transitional
bridge through the wound healing cascade between the M1
and the wound healing macrophages (M2). The presence of
quantifiable IL-10, and a lack of quantifiable VEGF, would
indicate that the macrophages resided within this regulatory
phenotype and had not progressed to the M2 phenotype
[31, 32]. It may be possible that longer duration culture
would have initiated the expression of the M2 phenotype and
possible VEGF production, and this may be investigated in
the future.
Another interesting result provided by these in vitro cellhoney interaction studies was the potential for the Manuka
honey products to become cytotoxic. In nearly all the studies
performed, with all three cell types utilized, concentrations
of Manuka honey or MH of 5% v/v and above resulted in the
death of the cells to be studied. It is hypothesized that this
cytotoxicity was due to the acidic pH and the closed nature
of the in vitro studies performed. To the authors’ knowledge,
there have been no reports of any Manuka products being

cytotoxic when used clinically. In a clinical setting, there are
far better mechanisms for diﬀusion, nutrient exchange, and
waste removal than there are in an in vitro study, where cells
are essentially sequestered and highly responsive to changes
in local pH. For this reason, it is highly likely that this preliminary in vitro study may not demonstrate the true potential
of using a Manuka honey product in a wound healing capacity and further in vivo and in situ studies will be required.
It may be possible that the promising results achieved here
with low concentrations of honey may be surpassed with
higher honey concentrations in an in vivo setting, where the
eﬀects of localized pH changes will be less inhibitory.
While the presence of PRGF and Manuka/MH supplemented media proved eﬀective in stimulating a positive
cellular response individually, the use of PRGF+MH media
demonstrated a further increase in cellular activity. This
impact was seen most clearly in the hDF-based studies,
and the in vitro wound healing assay study, where the
PRGF+MH media supplements resulted in statistically significant increases in cell proliferation and migration. As previously stated, this increase in cellular response may be due
to the presence of physiologically activated growth factors
such as TGF-β. However, this may only be a small part of the
overall potential for the PRGF+MH combination to increase
cellular activity. It is entirely possible that since the individual PRGF and MH components each provide necessary
pieces of the tissue regeneration puzzle, the combination of
PRGF+MH may provide an ideal combination to stimulate
wound healing. However, determining the exact mechanism
of cell stimulation is beyond the scope of this preliminary
study and will need to be evaluated in future work. While
the PRGF+MH yielded results that exceeded the authors’
expectations in the hDF-specific studies, the angiogenesis
studies proved to be less conclusive. This would signify that
the impact on the initiation of angiogenesis was due to
the presence of PRGF alone and was not influenced by the
addition of the Manuka/MH. This may indicate that the rate
of sprout formation and angiogenesis are highly dependent
upon the presence of available VEGF, readily found in
PRGF, in which case the presence of honey would not oﬀer
much benefit. However, it was anticipated that the pH of the
honey products alone may be enough to induce sprout
formation, as it has been documented that an acidic environment may promote angiogenesis [2, 4]. Therefore, as previously mentioned, these results may be indicative of the need
for an in vivo angiogenesis model.
In summary, PRP/PRGF capitalizes on the body’s own
initial healing component, the platelet, and concentrating
them to thereby concentrate their inherent growth factors
and “jump start” the healing process. In the lyophilized powdered form, the PRGF powder becomes more versatile (i.e.,
able to be stored in a vacuum sealed package) and less messy
than the liquid PRP while retaining its potent bioactive properties. Additionally, it may be possible that this powdered
PRGF, further enhanced through the addition of a MH product, may be carried by first responders or military personnel
to be used at the time of injury. It is anticipated that not only
will the application of a PRGF and Manuka honey product
accelerate the healing process, as demonstrated with the
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Figure 7: Representative light microscopy images of the in vitro bead angiogenesis assay performed with hPMECs cultured on Cytodex
beads. The 0.1% MH, 0.1 mg/mL PRGF, 1 mg/mL PRGF, PRGF+MH, and control are shown on days 1, 4, and 6 as those test medias resulted
in maximum sprout formation (a). Mean sprout densities (b, left) and mean sprout lengths (b, right) are shown for MH, PRGF, and control
medias. The results of Manuka honey supplemented media are not included as they were not significantly diﬀerent from those of MH.
Higher honey concentrations (5, 10, and 20% v/v) were excluded from the sprout density and sprout length graphs as they resulted in cell
death.
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in vitro results described here, but may also promote coagulation and provide antibacterial properties to a wound in the
field. It may also be possible that such a combination product
could prove to be highly eﬀective in treating chronic wounds,
where cellular senescence, low tissue friability, and biofilm
formation are all concerns. Having an essentially “all natural”
product known to be highly antibacterial, yet capable of
stimulating a number of diﬀerent cell types, at a patient’s
bedside capable of advancing the wound from a state of
chronic inflammation to a more conducive healing state
would be of great benefit to the treatment of chronic wounds.

5. Conclusion
In this study, it was demonstrated that a number of cell
types critical to dermal regeneration (hDF, hPMEC, and
macrophages) are capable of being positively influenced by
the presence of PRGF and Manuka honey media supplements. Based upon these results, it is apparent that PRGF
has the capacity to enhance cellular chemotaxis, mitogenesis,
ECM production, and angiogenesis. This bioactivity can be
further augmented by combining PRGF with MH, potentially due to the increased presence of growth factors that
have become physiologically activated. The precise nature of
this enhancement is not currently understood and may stem
from a number of attributes unique to the two materials
acting concomitantly: the presence of necessary sugars,
growth factors physiologically activated through Manuka
honey pH, direct pH eﬀects on cells, the presence of
Vitamin C, and others. While further research is needed to
definitively determine the method of action in which the
PRGF and MH permutation promote cellular activity, the
use of this combination of materials has great potential from
a regenerative medicine perspective; being able to apply a
lyophilized PRGF powder, with or without a Manuka honey
product, to the site of a dermal wound at the time of injury
may not only assist with clotting but may also accelerate
closure and healing of the wound. Ongoing work includes in
vivo evaluations of wound healing and angiogenesis in small
animal models, in vitro antibacterial investigation, as well as
in vitro work with a human keratinocyte cell line.
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